|
1
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar
|
|
2
|
Park SH, Song CW, Kim YB, Kim YS, Chun HR,
Lee JH, Seol WJ, Yoon HS, Lee MK, Lee JH, et al:
Clinicopathological characteristics of colon cancer diagnosed at
primary health care institutions. Intest Res. 12:131–138. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee CK: Clinicopathological
characteristics of newly diagnosed colorectal cancers in community
gastroenterology practice. Intest Res. 12:87–89. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim ER and Kim YH: Clinical application of
genetics in management of colorectal cancer. Intest Res.
12:184–193. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Riethdorf S, Wikman H and Pantel K:
Review: Biological relevance of disseminated tumor cells in cancer
patients. Int J Cancer. 123:1991–2006. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chambers AF, Groom AC and MacDonald IC:
Dissemination and growth of cancer cells in metastatic sites. Nat
Rev Cancer. 2:563–572. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mittal K, Ebos J and Rini B: Angiogenesis
and the tumor microenvironment: Vascular endothelial growth factor
and beyond. Semin Oncol. 41:235–251. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhao Y and Adjei AA: Targeting
angiogenesis in cancer therapy: Moving beyond vascular endothelial
growth factor. Oncologist. 20:660–673. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gomes FG, Nedel F, Alves AM, Nör JE and
Tarquinio SB: Tumor angiogenesis and lymphangiogenesis:
Tumor/endothelial crosstalk and cellular/microenvironmental
signaling mechanisms. Life Sci. 92:101–107. 2013. View Article : Google Scholar :
|
|
10
|
Stacker SA, Williams SP, Karnezis T,
Shayan R, Fox SB and Achen MG: Lymphangiogenesis and lymphatic
vessel remodelling in cancer. Nat Rev Cancer. 14:159–172. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Duong T, Koopman P and Francois M: Tumor
lymphangiogenesis as a potential therapeutic target. J Oncol.
2012:2049462012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Marques I, Araújo A and de Mello RA:
Anti-angiogenic therapies for metastatic colorectal cancer: Current
and future perspectives. World J Gastroenterol. 19:7955–7971. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Royston D and Jackson DG: Mechanisms of
lymphatic metastasis in human colorectal adenocarcinoma. J Pathol.
217:608–619. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun XF and Zhang H: Clinicopathological
significance of stromal variables: Angiogenesis, lymphangiogenesis,
inflammatory infiltration, MMP and PINCH in colorectal carcinomas.
Mol Cancer. 5:432006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang W, Meng Y, Liu N, Wen XF and Yang T:
Insights into chemoresistance of prostate cancer. Int J Biol Sci.
11:1160–1170. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ojha R, Bhattacharyya S and Singh SK:
Autophagy in cancer stem cells: A potential link between
chemoresistance, recurrence, and metastasis. Biores Open Access.
4:97–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang X, Li X, Fu X, Bai M, Li X, Mei Q,
Nie J, Wu Z and Han W: Eliminating ovarian cancer stem cells: A
potential therapeutic target for ovarian cancer chemoresistance.
Curr Protein Pept Sci. 16:270–278. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Carta A, Chetcuti R and Ayers D: An
introspective update on the influence of miRNAs in breast carcinoma
and neuroblastoma chemoresistance. Genet Res Int.
2014:7430502014.PubMed/NCBI
|
|
19
|
Hoshiba T and Tanaka M: Optimization of
the tissue source, malignancy, and initial substrate of tumor
cell-derived matrices to increase cancer cell chemoresistance
against 5-fluorouracil. Biochem Biophys Res Commun. 457:353–357.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Garza-Treviño EN, Said-Fernández SL and
Martínez-Rodríguez HG: Understanding the colon cancer stem cells
and perspectives on treatment. Cancer Cell Int. 15:22015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Paldino E, Tesori V, Casalbore P,
Gasbarrini A and Puglisi MA: Tumor initiating cells and
chemoresistance: Which is the best strategy to target colon cancer
stem cells? Biomed Res Int. 2014:8598712014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Grossi V, Peserico A, Tezil T and Simone
C: p38α MAPK pathway: A key factor in colorectal cancer therapy and
chemoresistance. World J Gastroenterol. 20:9744–9758. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lu Y, Yao HP and Wang MH: Multiple
variants of the RON receptor tyrosine kinase: Biochemical
properties, tumorigenic activities, and potential drug targets.
Cancer Lett. 257:157–164. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Leonis MA, Thobe MN and Waltz SE:
Ron-receptor tyrosine kinase in tumorigenesis and metastasis.
Future Oncol. 3:441–448. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Camp ER, Liu W, Fan F, Yang A, Somcio R
and Ellis LM: RON, a tyrosine kinase receptor involved in tumor
progression and metastasis. Ann Surg Oncol. 12:273–281. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang MH, Yao HP and Zhou YQ: Oncogenesis
of RON receptor tyrosine kinase: A molecular target for malignant
epithelial cancers. Acta Pharmacol Sin. 27:641–650. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang MH, Wang D and Chen YQ: Oncogenic and
invasive potentials of human macrophage-stimulating protein
receptor, the RON receptor tyrosine kinase. Carcinogenesis.
24:1291–1300. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wagh PK, Peace BE and Waltz SE:
Met-related receptor tyrosine kinase Ron in tumor growth and
metastasis. Adv Cancer Res. 100:1–33. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Danilkovitch-Miagkova A: Oncogenic
signaling pathways activated by RON receptor tyrosine kinase. Curr
Cancer Drug Targets. 3:31–40. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee CT, Chow NH, Su PF, Lin SC, Lin PC and
Lee JC: The prognostic significance of RON and MET receptor
coexpression in patients with colorectal cancer. Dis Colon Rectum.
51:1268–1274. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Park YL, Lee GH, Kim KY, Myung E, Kim JS,
Myung DS, Park KJ, Cho SB, Lee WS, Jung YD, et al: Expression of
RON in colorectal cancer and its relationships with tumor cell
behavior and prognosis. Tumori. 98:652–662. 2012.PubMed/NCBI
|
|
32
|
Song YA, Park YL, Kim KY, Myung E, Chung
CY, Cho SB, Lee WS, Jung YD, Kweon SS and Joo YE: RON is associated
with tumor progression via the inhibition of apoptosis and cell
cycle arrest in human gastric cancer. Pathol Int. 62:127–136. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Maggiora P, Marchio S, Stella MC, Giai M,
Belfiore A, De Bortoli M, Di Renzo MF, Costantino A, Sismondi P and
Comoglio PM: Overexpression of the RON gene in human breast
carcinoma. Oncogene. 16:2927–2933. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim SA, Yoon TM, Lee DH, Park YL, Lee KH,
Lim SC, Joo YE and Lee JK: RON (recepteur d'origine Nantais)
expression and its association with tumor progression in laryngeal
squamous cell carcinoma. Auris Nasus Larynx. 41:201–206. 2014.
View Article : Google Scholar
|
|
35
|
Yoon TM, Kim SA, Park YL, Lee KH, Sung MW,
Lee JK, Lim SC, Chung IJ and Joo YE: Expression of the receptor
tyrosine kinase recepteur d'origine Nantais and its association
with tumor progression in hypopharyngeal cancer. Head Neck.
35:1106–1113. 2013. View Article : Google Scholar
|
|
36
|
Chung CY, Park YL, Song YA, Myung E, Kim
KY, Lee GH, Ki HS, Park KJ, Cho SB, Lee WS, et al: Knockdown of RON
inhibits AP-1 activity and induces apoptosis and cell cycle arrest
through the modulation of Akt/FoxO signaling in human colorectal
cancer cells. Dig Dis Sci. 57:371–380. 2012. View Article : Google Scholar
|
|
37
|
Cho SB, Park YL, Song YA, Kim KY, Lee GH,
Cho DH, Myung DS, Park KJ, Lee WS, Chung IJ, et al: Small
interfering RNA-directed targeting of RON alters invasive and
oncogenic phenotypes of human hepatocellular carcinoma cells. Oncol
Rep. 26:1581–1586. 2011.PubMed/NCBI
|
|
38
|
American Joint Committee on Cancer
Classification (AJCC): Cancer Staging Manual. 6th edition. revised.
Lippincott-Raven; Philadelphia: pp. 113–123. 2002
|
|
39
|
Paschall AV and Liu K: Epigenetic
regulation of apoptosis and cell cycle regulatory genes in human
colon carcinoma cells. Genom Data. 5:189–191. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mason EF and Rathmell JC: Cell metabolism:
An essential link between cell growth and apoptosis. Biochim
Biophys Acta. 1813:645–654. 2011. View Article : Google Scholar
|
|
41
|
Schultz DR and Harrington WJ Jr:
Apoptosis: Programmed cell death at a molecular level. Semin
Arthritis Rheum. 32:345–369. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Morgan DO: Principles of CDK regulation.
Nature. 374:131–134. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Graña X and Reddy EP: Cell cycle control
in mammalian cells: Role of cyclins, cyclin dependent kinases
(CDKs), growth suppressor genes and cyclin-dependent kinase
inhibitors (CKIs). Oncogene. 11:211–219. 1995.PubMed/NCBI
|
|
44
|
Johnson N and Shapiro GI: Cyclin-dependent
kinases (cdks) and the DNA damage response: Rationale for cdk
inhibitor-chemotherapy combinations as an anticancer strategy for
solid tumors. Expert Opin Ther Targets. 14:1199–1212. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang D, Shen Q, Xu XM, Chen YQ and Wang
MH: Activation of the RON receptor tyrosine kinase attenuates
transforming growth factor-beta1-induced apoptotic death and
promotes phenotypic changes in mouse intestinal epithelial cells.
Carcinogenesis. 26:27–36. 2005. View Article : Google Scholar
|
|
46
|
Danilkovitch-Miagkova A, Miagkov A, Skeel
A, Nakaigawa N, Zbar B and Leonard EJ: Oncogenic mutants of RON and
MET receptor tyrosine kinases cause activation of the beta-catenin
pathway. Mol Cell Biol. 21:5857–5868. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Thobe MN, Gurusamy D, Pathrose P and Waltz
SE: The Ron receptor tyrosine kinase positively regulates
angiogenic chemokine production in prostate cancer cells. Oncogene.
29:214–226. 2010. View Article : Google Scholar :
|
|
48
|
Karnezis T, Shayan R, Fox S, Achen MG and
Stacker SA: The connection between lymphangiogenic signalling and
prostaglandin biology: A missing link in the metastatic pathway.
Oncotarget. 3:893–906. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Maggiora P, Lorenzato A, Fracchioli S,
Costa B, Castagnaro M, Arisio R, Katsaros D, Massobrio M, Comoglio
PM and Flavia Di Renzo M: The RON and MET oncogenes are
co-expressed in human ovarian carcinomas and cooperate in
activating invasiveness. Exp Cell Res. 288:382–389. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cheng HL, Liu HS, Lin YJ, Chen HH, Hsu PY,
Chang TY, Ho CL, Tzai TS and Chow NH: Co-expression of RON and MET
is a prognostic indicator for patients with transitional-cell
carcinoma of the bladder. Br J Cancer. 92:1906–1914. 2005.
View Article : Google Scholar : PubMed/NCBI
|
